Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune)
This study has been completed.
Study NCT01345916   Information provided by Chiesi Farmaceutici S.p.A.

First Received on April 12, 2011.   Last Updated on February 14, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
More general conditions related to this trial
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Interventions listed in this trial
CHF 1535 100/6 NEXT DPI® 2 months
CHF 1535 100/6 pMDI 2 months
BDP DPI 2 months
Additional drug interventions recognized in this trial
Beclomethasone
More general drug interventions related to this trial
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
Chiesi Farmaceutici S.p.A.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services